Form 4: Myriad Genetics Director Lee Nisley Newcomer Acquires Over 49,000 Shares in RSU Grant

Myriad Genetics Inc. Director Lee Nisley Newcomer reported the acquisition of 49,796 shares of common stock through a restricted stock unit grant on June 5, 2025, increasing her total beneficial ownership to 132,141 shares.

Summary

• Lee Nisley Newcomer, a Director of Myriad Genetics Inc. (MYGN), acquired 49,796 shares of common stock on June 5, 2025.
• The acquisition was a grant of restricted stock units (RSUs) with a reported price of $0 per share.
• These RSUs were granted pursuant to Myriad Genetics, Inc.'s 2017 Employee, Director and Consultant Equity Incentive Plan, as amended.
• Each restricted stock unit represents a contingent right to receive one share of common stock.
• The RSUs vest upon the earlier of the first anniversary of the grant date (June 5, 2026) or the date of the next annual meeting of stockholders following such grant.
• Following this transaction, Lee Nisley Newcomer's total beneficial ownership in Myriad Genetics Inc. stands at 132,141 shares of common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even through a grant, is generally a positive signal as it increases their stake and aligns their interests with shareholders. It's a routine compensation event, not a major strategic announcement, hence a moderately positive score.

Positives

• The acquisition of 49,796 shares by a director through an RSU grant indicates continued alignment of management interests with shareholder interests.
• The grant of restricted stock units is a common form of equity compensation, incentivizing long-term performance and retention of key personnel.

Risks

• The value of the granted restricted stock units is subject to the future performance of Myriad Genetics' common stock.
• The vesting conditions (one year or next annual meeting) mean the shares are not immediately liquid for the director.

Future Outlook

The restricted stock units are expected to vest upon the earlier of the first anniversary of the grant date (June 5, 2026) or the date of the next annual meeting of stockholders following the grant.

Industry Context

This Form 4 filing reports a routine insider transaction, specifically an equity grant to a director. Such grants are a common practice across various industries, including biotechnology and genetics, to align the interests of directors and executives with those of shareholders by providing them with a direct stake in the company's long-term performance.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to a director is a standard form of equity compensation widely adopted by publicly traded companies across industries, including the biotechnology sector, to incentivize long-term commitment and performance.
• The vesting schedule, typically tied to a time-based period (e.g., one year) or a specific corporate event (e.g., next annual meeting), is also a common practice designed to retain key personnel and align their interests with sustained shareholder value creation.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to increased equity ownership.
• Employees/Management: Reflects standard equity compensation practices for directors, which can be seen as a positive for overall compensation strategy.

Next Steps

• The restricted stock units are expected to vest upon the earlier of June 5, 2026, or the date of the next annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Myriad Genetics, MYGN, Form 4, Insider Trading, Restricted Stock Units, RSU, Equity Compensation, Director Stock Acquisition, Beneficial Ownership, SEC Filing, Biotechnology, Genetics